Anti-HER2 Antibody-drug Conjugate BL-M07D1 clinical trials
Its developmentBy Sichuan Biokin Pharmaceutical, step by step21 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-HER2 Antibody-drug Conjugate BL-M07D1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-HER2 Antibody-drug Conjugate BL-M07D1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- BL-M07D1
- 21
Studies by the year they started
21 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 0
Sichuan Baili Pharmaceutical Co., Ltd. (19) · SystImmune Inc. (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 2 in phase 3
Studies that test Anti-HER2 Antibody-drug Conjugate BL-M07D1, phase 3 first.
- May 2027A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerPhase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Jun 2027A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction AdenocarcinomaPhase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsPhase 1 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsPhase 1 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal TumorsPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Jan 2027A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic MalignanciesPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-HER2 Antibody-drug Conjugate BL-M07D1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingPhase 3SystImmune Inc.NCT07869836Written as T-Bren, Dose level 1
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT06891833Written as BL-M07D1
- A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic MalignanciesRecruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT06131450Written as BL-M07D1
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingPhase 1SystImmune Inc.NCT06293898Written as BL-M07D1
- A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07678957Written as BL-M07D1
- A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07730489Written as BL-M07D1
- A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05461768Written as BL-M07D1
- Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05631964Written as BL-M07D1
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as BL-M07D1
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07545460Written as BL-M07D1
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07518173Written as BL-M07D1
- A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal TumorsRecruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT06031584Written as BL-M07D1
- A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07264816Written as BL-M07D1
- A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06830889Written as BL-M07D1
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06957886Written as BL-M07D1
- A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07178795Written as BL-M07D1
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction AdenocarcinomaRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07152405Written as BL-M07D1
- A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT06114511Written as BL-M07D1
- A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06423885Written as BL-M07D1
- A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06445400Written as BL-M07D1
See all 21 studies that test Anti-HER2 Antibody-drug Conjugate BL-M07D1 →